Zacks.com on MSN5d
GSK Gets EC Nod for Liquid Version of Meningococcal Vaccine MenveoGSK plc GSK announced that the European Commission (EC) has approved a single-vial, fully liquid presentation of its ...
GlobalData on MSN5d
EC approves GSK’s Menveo vaccine presentation for IMDThe European Commission (EC) has granted approval for a single-vial, fully liquid presentation of GSK's Menveo vaccine ...
GSK’s fully liquid presentation of its meningococcal vaccine Menveo has been approved by the European Commission (EC) to ...
The European Commission (EC) has approved a single-vial, fully liquid presentation of Menveo (meningococcal Group A, C, W-135 ...
GSK (GSK) announced that the European Commission, EC, has approved a single-vial, fully liquid presentation of Menveo to help protect against ...
The European Commission (EC) has granted approval for a single-vial, fully liquid presentation of GSK's Menveo vaccine (MenACWY), designed to protect against invasive meningococcal disease (IMD ...
GSK (GSK) announced that the European Commission, EC, has approved a single-vial, fully liquid presentation of Menveo to help protect against invasive meningococcal disease, IMD, caused by ...
GSK's liquid meningitis vaccine, Menveo, received approval from the European Commission to be sold in the European Union. The British pharmaceutical company said Wednesday that the fully liquid ...
In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback